New And Noteworthy Approvals From 2017

Having just discussed some of the important approvals from 2017, we wanted to dive deeper into other therapeutic areas, and also cover new device and digital health approvals. Below, we recap other significant approvals from this year.

Regeneron Pharmaceuticals and Sanofi | March 2017
Moderate-to-severe eczema (atopic dermatitis)

First biologic medication approved for this skin condition that results in cracked, dry, itching or oozing skin. It follows several approvals for biologics for psoriasis and other psoriatic conditions in recent years.

Neurocrine Biosciences | April 2017
Tardive dyskinesia

First drug approved to treat the abnormal, involuntary movements characteristic of tardive dyskinesia, a serious side effect sometimes seen in patients who have taken antipsychotic medications.

Teva Pharmaceuticals | April 2017
Maintenance treatment of asthma

Competitor to GlaxoSmithKline’s Advair, a blockbuster asthma drug, with the same active ingredient. Generic competition is still pending.

Samsung Bioepis | April 2017
Rheumatoid arthritis, adult ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease

Second biosimilar approved in the US to Janssen’s Remicade.

BioMarin Pharmaceutical | April 2017
Batten disease

Enzyme replacement therapy for a pediatric neurologic disease that helps children retain the ability to crawl or walk.

Mitsubishi Tanabe Pharma Corp. | May 2017
Amyotrophic lateral sclerosis (ALS) (Lou Gehrig’s disease)

After a six month trial conducted only in Japan yielded positive results, the FDA approached the company for a US filing for the drug.

Emmaus Life Sciences | July 2017
Amino acid deficiency resulting from sickle cell disease

Indicated to prevent sickle cell attacks. Approval thought to bode favorably for Global Blood Therapeutics’ GBT-440, currently in Phase III study.

Gilead Sciences | July 2017
Hepatitis C

First drug combination approved to treat all genotypes of the hepatitis C virus.

Novartis | August 2017
Relapsed acute lymphoblastic lymphoma

First CAR-T product approved.

Boehringer Ingelheim | August 2017
Rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis

Second biosimilar to AbbVie’s popular Humira approved in the US. Launch date is unknown due to patent disputes.

Allergan and Amgen | September 2017
Metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer

First biosimilar to Genentech’s Avastin. Not approved in three indications still protected by orphan exclusivity – ovarian, fallopian tube, and primary peritoneal cancers. Commercial launch not expected before 2019.

Abbott Diabetes Care | September 2017
Blood glucose monitoring

First continuous glucose monitoring system that does not require blood sample calibration.

Mylan Pharmaceuticals | October 2017
Relapsing-remitting multiple sclerosis

Generic to Teva’s best selling Copaxone. While not a true biosimilar, Copaxone is a complex biologic drug to manufacture.

Kite Pharma, a Gilead company | October 2017
Relapsed or refractory diffuse large-B cell lymphoma

Second CAR-T approval in the US.

Dynavax | November 2017
Hepatitis B vaccine

Two dose vaccine Toll-Like Receptor 9 agonist that increases immune response. Existing vaccines are three doses.

Otsuka and Proteus Digital Health | November 2017
Bipolar disorder, major depressive disorder, and schizophrenia

Drug contains a sensor to track ingestion. When the sensor comes in contact with a patient’s stomach acid, a signal goes to a patch worn by the patient as a way to measure adherence.

ViiV Healthcare | November 2017

First two-drug combination to treat HIV, compared to conventional three drug combinations.

Indivior | November 2017
Opioid use disorder

First once-monthly injection of buprenorphine, compared to daily doses or weekly patches.

Mylan Pharmaceuticals | December 2017
Certain breast or metastatic stomach cancers

First biosimilar to Herceptin. Launch date unknown.

Spark Therapeutics | December 2017
RPE65 mutation-associated retinal dystrophy

First US gene therapy approval.